Harvard Bioscience (NASDAQ:HBIO) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

Harvard Bioscience, Inc. (NASDAQ:HBIO) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.84 and traded as high as $6.32. Harvard Bioscience shares last traded at $6.23, with a volume of 14,399 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HBIO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a report on Wednesday, June 24th. Wall Street Zen cut shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Harvard Bioscience currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Harvard Bioscience Stock Up 4.7%

The stock has a 50 day moving average price of $5.99 and a 200 day moving average price of $5.84. The company has a current ratio of 1.99, a quick ratio of 1.06 and a debt-to-equity ratio of 3.60. The company has a market capitalization of $28.10 million, a P/E ratio of -2.87 and a beta of 1.49.

Harvard Bioscience (NASDAQ:HBIO) last announced its earnings results on Tuesday, May 12th. The medical instruments supplier reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.29. Harvard Bioscience had a negative return on equity of 25.78% and a negative net margin of 11.44%.The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $21.20 million.

Institutional Investors Weigh In On Harvard Bioscience

Large investors have recently modified their holdings of the company. Nano Cap New Millennium Growth Fund L P acquired a new stake in Harvard Bioscience during the 4th quarter worth about $401,000. Meros Investment Management LP boosted its position in shares of Harvard Bioscience by 32.6% during the 4th quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after purchasing an additional 299,369 shares in the last quarter. Legato Capital Management LLC grew its stake in Harvard Bioscience by 210.4% during the fourth quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 29,462 shares during the period. XTX Topco Ltd bought a new stake in Harvard Bioscience in the fourth quarter worth approximately $26,000. Finally, Essex Investment Management Co. LLC acquired a new position in Harvard Bioscience in the fourth quarter valued at approximately $124,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.